References
- Anonymous (2013). Open Source Epidemiologic Statistic for Public Health. Available at: http://www.openepi.com/v37/Menu/OE_Menu.htm (accessed 25.11.2013).
- Chen, K., Kolls, J. K. (2013). T Cell-Mediated Host Immune Defenses in the Lung. Ann. Rev. Immunol., 31, 605-633.
- Cheng, S. M., Li, J. C. B., Lin, S. S., Lee, D. C. W., Liu, L., Chen, Z., Lau, A. S. Y. (2009). HIV-1 transactivator protein induction of suppressor cytokine signaling-2 contributes to dysregulation of IFN-g signaling. Blood, 13, 5192-5201.
- Getahun, H., Gunneberg, C., Granich, R., Nunn, P. (2010). HIV infection- associated tuberculosis: The epidemiology and the response. Clin. Infect. Dis., 50 (Suppl. 3), S201-S207.
- Boekhoudt, G. H., McGrath, A. G., Swisher, J. F., Feldman, G. M. (2015). Immune complexes suppress IFN-γ-induced responses in monocytes by activating discrete members of the SRC kinase family. J. Immunol., 194 (3), 983-989.
- Klein, S. A., Dobmeyer, J. M., Dobmeyer, T. S., Pape, M., Ottmann, O. G., Helm, E. B., Hoelzer, D., Rossol, R. (1997). Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS, 11, 1111-1118.
- Li, J. C. B., Au, K., Fang, J., Yim, H. C. H., Chow, K., Ho, P., Lau, A. S. Y. (2011). HIV-1 trans-activator protein dysregulates IFN-g signaling and contributes to the suppression of autophagy induction. AIDS, 25, 15-25.
- Modjarrad, K., Vermund, S. H. (2010). Effect of treating co-infections on HIV-1 viral load: A systematic review. Lancet Infect. Dis., 10, 455-463.
- Moller, M., Hoal, E. G. (2010). Current findings, challenges and novel approaches inhuman genetic susceptibility to tuberculosis. Tuberculosis (Edinburg), 90, 71-83.
- Osakwe, C. E., Bleotu, C., Chifiriuc, M. C., Crancea, C., Otelea, D., Paraschiv, S., Petrea, S., Dinu, M., Baicus, C., Streinu-Cercel, A., Lazar, V. (2010). TH1/TH2 cytokine levels as an indicator for disease progression in human immunodeficiency virus type 1 infection and response to antiretroviral therapy. Roum. Arch. Microbiol. Immunol., 69 (1), 24-34.
- Pawlowski, A., Jansson, M., Sköld, M., Rottenberg, M. E., Källenius, G. (2012). Tuberculosis and HIV co-infection. PLoS Pathog., 8 (2), e1002464.
- Roff, S. R, Noon-Song, E. N., Yamamoto, J. K. (2013). The significance of interferon-g in HIV-1 pathogenesis, therapy, and prophylaxis. Frontiers Immunol., 4, 498. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888948/ (accessed 20.05.2016).
- Selwyn, P. A., Hartel, D., Lewis, V. A., Schoenbaum, E. E., Vermund, S. H., Klein, R. S., Walker, A. T., Friedland, G. H. (1989). A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. New Engl. J. Med., 320, 545-555.
- Spellberg, B., Edwards, J. E., Jr. (2001). Type 1/type 2 immunity in infectious diseases. Clin. Infect. Dis., 32 (1), 76-102.
- Young, H. A., Hardy, K. J. (1995). Role of interferon-gamma in immune cell regulation. J. Leukocyte Biol., 58 (4), 373-381.
- Whalen, C., Horsburgh, C. R., Hom, D., Lahart, C., Simberkoff, M., Eller, J. (1995). Accelerated course of human immunodeficiency virus infection after tuberculosis. Amer. J. Respir. Crit. Care Med., 151, 129-135.